Andrew Hirsch bound to BIND as CFO
This article was originally published in Scrip
BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins, has appointed Andrew Hirsch CFO. Mr Hirsch previously served as CFO at Avila Therapeutics before its acquisition by Celgene in March 2012. Prior to that, he worked at Biogen Idec for nearly a decade.